Resistant diabetic macular edema may necessitate transitioning from one intravitreal pharmacotherapy to another when the edema is persistent — a practice sometimes undertaken in clinical management.

PRINCETON, N.J., July 23, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANIP) today announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0 ...

Although corticosteroids were found to immediately improve best-corrected visual acuity and central macular thickness, anti–vascular endothelial growth factor (anti-VEGF) therapies had significant ...

ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...

Please provide your email address to receive an email when new articles are posted on . Dr. Noemi Lois is a clinical professor at Queen’s University Belfast and a consultant ophthalmologist and ...

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial disease burden for patients. Several organizations have published clinical guidelines on ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The drug also showed potential efficacy in patients who failed to optimally ...

In photographs of the eye used to screen for diabetes-related eye disease, separating out the red color channel can help show some abnormalities—especially in racial/ethnic minority patients, suggests ...

Meaningful vision gains are rapidly achieved as early as week 4 and more than half of patients in the top two dose levels improved 3-lines or more on the eye chart (≥15 letter gain) A single dose of ...